Quick answer
When your biopsy shows prostate cancer, the first step is to know your risk group, which combines the ISUP grade group from the biopsy, the PSA and the rectal exam.1 It tells you whether more scans are needed, such as a PSMA PET, and which treatments make sense: active surveillance, surgery or radiotherapy.2,3 In most cases there is time to understand the report and decide calmly.9 When I recommend surgery for intermediate- or high-risk disease, I advise operating as soon as possible.
First, understand what you have
A cancer diagnosis is frightening, and many men want to sort everything out in the same week. Localised prostate cancer, however, almost always leaves time to understand the report, complete the scans and learn about the options before choosing.9
The page is prostate cancer curable? explains what the numbers show. This page focuses on the first few weeks.
What to look for in the biopsy report
The report says more than the word cancer. These are the details that weigh most in the decision:
- Gleason score and ISUP grade group: they measure how aggressive the tumor looks under the microscope. The grade group goes from 1 to 5, and group 1 (Gleason 3+3=6) is the lowest.2 The page on Gleason and ISUP explains each grade.
- Positive cores: how many cores were taken and how many contained tumor. For a systematic biopsy, the European guideline asks for at least 12 cores.2
- How much of each core: the extent of tumor, in millimetres or as a percentage. Both have the same prognostic weight, and the report should give the number of positive cores and the extent in each one.2
- Pattern 4: in Gleason 7, the European guideline advises recording the percentage of pattern 4.2
The number of positive cores also splits intermediate risk into two groups. In the American NCCN guideline, half or more of the cores with cancer places the case in unfavourable intermediate risk.5,6
Your risk group
The European guideline divides prostate cancer into risk groups by ISUP grade group, PSA and rectal exam:1
| Group | How it is defined |
|---|---|
| Low risk | ISUP 1, PSA below 10 ng/mL and tumor confined to the prostate on rectal exam |
| Intermediate risk | ISUP 2 or 3, or PSA between 10 and 20 ng/mL, with tumor confined to the prostate on rectal exam |
| High risk | ISUP 4 or 5, or PSA above 20 ng/mL |
| Locally advanced | Tumor beyond the prostate on rectal exam (cT3 or cT4) or suspicious lymph nodes on imaging, with any ISUP and any PSA |
The risk group calculator works this out from your report. The pages on intermediate risk and high risk explain each group in detail.
Staging scans
Staging means finding out how far the cancer has gone. The European guideline uses the MRI done before the biopsy to look at the prostate and the area around it. Other scans depend on the risk group:2
| Group | What the European guideline advises |
|---|---|
| Low risk or favourable intermediate risk | No further imaging for staging |
| Unfavourable intermediate risk | PSMA PET, if available, or at least abdominal and pelvic CT with a bone scan |
| High risk or locally advanced | PSMA PET, if available, or at least abdominal and pelvic CT with a bone scan |
In the proPSMA trial, with 302 high-risk men, accuracy was 92% with PSMA PET and 65% with CT and bone scan.7 Men with bone pain have a bone scan whatever their risk group.2
Treatment options
With the risk group and the scans, the conversation moves to treatment. The American guideline asks for shared decision-making, weighing the risk of the cancer against the effects of each option on urine, erections and bowel.4
- Active surveillance: monitoring with PSA, MRI and repeat biopsies, and treating if the tumor changes. It is the standard approach for low-risk disease.3 Personally, I do not recommend active surveillance for intermediate risk, not even the favourable kind. The European guideline accepts it in carefully selected cases of ISUP 2.3
- Robotic radical prostatectomy: removal of the prostate and seminal vesicles. The European guideline offers it for intermediate-risk disease and, in selected patients, for high-risk disease.3
- Radiotherapy: for intermediate risk, it comes with 4 to 6 months of hormone therapy, and for high risk, with 2 to 3 years.3
In the ProtecT trial, 1,643 men were randomised to monitoring, surgery or radiotherapy and followed for 15 years. Deaths from the cancer were low in all three groups, but metastases were about twice as common with monitoring.8 The page surgery or radiotherapy compares the side effects of each.
You may also hear about focal therapies, which treat only the area of the tumor. The European guideline recommends them only within trials or registries.3 The page on focal therapy explains how they work.
How long you have to decide
A 2021 systematic review pooled 19 studies of men with intermediate- and high-risk disease. Waiting about 3 months generally did not worsen the pathology of the removed prostate, PSA recurrence or survival.9
That window is for completing the scans, getting a second opinion and deciding with confidence. In my practice, when I recommend surgery for intermediate- or high-risk disease, I advise operating as soon as possible. While you wait, hormone therapy is not indicated, because it has no role before prostatectomy.3
Second opinion
A second opinion helps confirm the risk group and lay out the options before you choose. At an American centre that reviewed the biopsies of 855 men referred for surgery, the Gleason score changed risk category in 14.7% of cases.10
In my practice, a second opinion can be done entirely online, in English. You send your results in advance, and we start from what you already have. Repeating tests is kept for very selected cases, and review of the slides by another pathologist for specific cases.
Questions to bring to your consultation
Write your questions down before the consultation. These usually help:
- What is my risk group, and what put me there?
- Do I need any more tests before deciding?
- Is active surveillance an option for me?
- What could surgery and radiotherapy change in my urine, erections and bowel?
- How long can I take to decide?
- What will follow-up look like after treatment?
Also bring the biopsy report, the MRI report and images, all your PSA results with dates and the list of medicines you take. If you can, bring a family member, who can help you remember what was discussed.
How I approach it
At the first consultation, I read the biopsy report, the MRI and the PSA results and explain which risk group your case falls into. If a staging scan is missing, I explain what the guideline recommends for your group. Then we talk through the options, with the numbers for each and what each treatment may affect.
I have a PhD from the University of São Paulo Medical School and have performed more than 1,500 robotic and laparoscopic operations, more than 500 of them robotic. I have performed robotic radical prostatectomy since 2020 and preserve the erection nerves whenever possible.
Send your case
If you have just been diagnosed and would like my opinion on your case before a consultation, fill in the form below. It goes to my office, and you will get a reply within 24 hours by email or WhatsApp. The form does not replace a consultation: it helps plan the next step.
Frequently asked questions
My biopsy showed prostate cancer. What should I do first?+
Gather the biopsy report, the MRI and all your PSA results and take them to a urologist. With the ISUP grade group, the PSA and the rectal exam, he or she defines your risk group, which guides the scans and the treatment options.1 In most cases there is time to understand the diagnosis calmly. In a review of 19 studies, waiting about 3 months generally did not worsen surgical outcomes in intermediate- and high-risk disease.9
What should I look for in the biopsy report?+
The Gleason score and ISUP grade group, how many cores contained cancer and how much of each core was involved. The European guideline asks the report to give the number of cancer-positive cores and the extent of cancer in each, and the length in millimetres and the percentage have the same prognostic weight.2
Do I need a PSMA PET or bone scan after the diagnosis?+
It depends on your risk group. In low-risk and favourable intermediate-risk disease, the European guideline advises against further imaging for staging. In unfavourable intermediate-risk and high-risk disease, it recommends PSMA PET, if available, or at least abdominal and pelvic CT with a bone scan.2
What are the treatment options for localised prostate cancer?+
The main ones are active surveillance, surgery and radiotherapy. Active surveillance is the standard approach for low-risk disease.3 For intermediate- and high-risk disease, the European guideline accepts radical prostatectomy and radiotherapy with hormone therapy.3 The American guideline asks for shared decision-making, weighing the risk of the cancer against the side effects of each treatment.4
How long can I wait before starting treatment?+
In a review of 19 studies in men with intermediate- and high-risk disease, waiting about 3 months generally did not worsen surgical outcomes.9 In my practice, when I recommend surgery for intermediate- or high-risk disease, I advise operating as soon as possible, without hormone therapy while the patient waits, because it is not indicated before prostatectomy.3
Does low-risk prostate cancer need surgery?+
Usually not. The European guideline recommends active surveillance as the standard approach for low-risk disease.3 In the ProtecT trial, after 15 years of follow-up, deaths from prostate cancer were low with monitoring, surgery and radiotherapy, but metastases were more common with monitoring.8
Is a second opinion worth it?+
Yes, especially if you heard about only one option or are unsure about your risk group. At an American centre that reviewed 855 biopsies before surgery, the Gleason score changed risk category in 14.7% of cases.10 In my practice, a second opinion can be done entirely online, in English, with your results sent in advance.
Who can I talk to about a new prostate cancer diagnosis in São Paulo?+
I see men who have just been diagnosed. I am Dr. Petronio Melo, a urologist and robotic surgeon in São Paulo, Brazil, with a PhD from the University of São Paulo Medical School and more than 1,500 robotic and laparoscopic operations, more than 500 of them robotic. I have performed robotic radical prostatectomy since 2020. The first consultation can be online, in English.
References
- EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer: classification and staging systems. European Association of Urology; 2026. EAU
- EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer: diagnostic evaluation. European Association of Urology; 2026. EAU
- EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer: treatment. European Association of Urology; 2026. EAU
- Eastham JA, Auffenberg GB, Barocas DA, et al. Clinically Localized Prostate Cancer: AUA/ASTRO Guideline (2022; amended 2026). American Urological Association; 2026. AUA
- Zumsteg ZS, Spratt DE, Pei I, et al. A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy. Eur Urol. 2013;64(6):895-902. PubMed
- Schaeffer EM, Srinivas S, Adra N, et al. NCCN Guidelines Insights: Prostate Cancer, Version 3.2024. J Natl Compr Canc Netw. 2024;22(3):140-150. PubMed
- Hofman MS, Lawrentschuk N, Francis RJ, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020;395(10231):1208-1216. PubMed
- Hamdy FC, Donovan JL, Lane JA, et al. Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N Engl J Med. 2023;388(17):1547-1558. PubMed
- Laukhtina E, Sari Motlagh R, Mori K, et al. Oncologic impact of delaying radical prostatectomy in men with intermediate- and high-risk prostate cancer: a systematic review. World J Urol. 2021;39(11):4085-4099. PubMed
- Brimo F, Schultz L, Epstein JI. The value of mandatory second opinion pathology review of prostate needle biopsy interpretation before radical prostatectomy. J Urol. 2010;184(1):126-130. PubMed
Would you like to talk about your case?
In the consultation, I go over your tests and your priorities.
Book a consultation5.0186 Google reviews
